E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036143 |
E.1.2 | Term | Pompe's disease |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of the study are:
• To evaluate the safety and tolerability of BMN 701
• To determine the anti-BMN 701 antibody response to BMN 701; and
• To determine the anti-IGF-I and anti-IGF-II antibody response to BMN 701.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives of the study are,:
• To determine the single-dose and multiple-dose PK of BMN 701; and
• To determine mobility and functional exercise capacity, as measured by the Six-Minute Walk Test (6MWT).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Patient has provided written informed consent after the nature of the study has been explained, and prior to any study-related procedures;
• Patient has been diagnosed with Pompe disease, either prior to, or during the screening period based on 2 GAA gene mutations and either o endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed in cultured skin fibroblasts,
o or,
o endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay;
• Patient is male or female and 18 years of age or older at the time of enrollment in the study;
• The patient, if sexually active, must be willing to use an acceptable method of contraception while participating in the study and for at least 4 months following the last dose of BMN 701;
• The patient, if female, is not considered to be of childbearing potential: that is she is at least 2 years post-menopausal or had tubal ligation at least 1 year prior to screening, or has had a total hysterectomy;
• The patient, if female of childbearing potential, has negative urine pregnancy tests during the Screening Period and at the Baseline visit and is willing to have additional pregnancy tests during the study;
• If patient is female, she is not lactating;
• Patient has ≥30% predicted upright FVC and either <80% predicted upright FVC or > 10% reduction in supine FVC compared to upright FVC during the Screening Period;
• Patient is naïve to ERT with rhGAA;
• Patient must be able to ambulate at least 40 meters (131.2 feet) on the 6MWT conducted at the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted); and
• Patient has the ability to comply with the protocol requirements, in the opinion of the Investigator. |
|
E.4 | Principal exclusion criteria |
•Patient has a history of diabetes or other disease known to cause hypoglycemia and is currently receiving, or might anticipate receiving, hypoglycemic agents during the course of the study;
• Patient has been on any immunosuppressive medication other than glucocorticosteroids within 1 year prior to enrollment into this study;
• Patient requires invasive ventilatory assistance at the time of enrollment into the study;
• Patient has received any investigational medication within 30 days prior to the first dose of study drug or is scheduled to receive any investigational drug other than BMN 701 during the course of the study;
• Patient has previously been admitted to the study;
• Patient is breastfeeding at screening or planning to become pregnant (self or partner) at any time during the study;
• Patient has a medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient’s ability to comply with the protocol requirements or compromise the patient’s well being or safety;
• Patient has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objectives of the study are:
• To evaluate the safety and tolerability of BMN 701;
• To determine the anti-BMN 701 antibody response to BMN 701
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Screening
Baseline
Day 1
Week 2-24 qow
30 Days after Week 24 |
|
E.5.2 | Secondary end point(s) |
Secondary objectives of the study are:
• To determine the single-dose and multiple-dose PK of BMN 701; and
• To determine mobility and functional exercise capacity, as measured by the Six-Minute Walk Test (6MWT).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Screening
Baseline
Day 1
Week 2-24 qow
30 Days after Week 24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Multiple dose escalation study |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Multiple dose escalation study |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Germany |
Netherlands |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end after the last patient has completed the Follow-up or Termination visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |